Mirum reports positive interim Ph2b data for volixibat in PBC and PSC

Mirum Pharmaceuticals, Inc.

VANTAGE PBC trial: volixibat achieved placebo-adjusted -2.32 point itch reduction (p=0.0026); 75% of patients had >50% drop in serum bile acids.
Significant fatigue improvement at week 16; no new safety signals; diarrhea (77%) mostly mild/moderate and transient; 4 SAEs (1 placebo).
VANTAGE and VISTAS PSC trials to continue with volixibat 20 mg twice daily; independent data review committee recommended continuation for PSC.
No clinically meaningful changes in liver biomarkers in PBC; sponsor remains blinded to interim results.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.